June 11 (Reuters) - Novavax Inc said on Friday its COVID-19 vaccine candidate showed immune response and protection against the SARS-CoV-2 Beta variant, which was originally identified in South Africa, in three animal and human studies. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.73 USD | -2.69% | +14.28% | +269.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+269.38% | 2.56B | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax : says COVID-19 vaccine candidate shows immune response against Beta variant